A case of severe hepatotoxicity induced by cisplatin and 5-fluorouracil

  • Ayaka YaegashiEmail author
  • Kensuke Yoshida
  • Naoto Suzuki
  • Izumi Shimada
  • Yusuke Tani
  • Yasuo Saijo
  • Akira Toyama
Case report


Severe hepatotoxicity from combination chemotherapy with cisplatin and 5-fluorouracil is a rare adverse effect. In this case report, we present a case with severe hepatotoxicity immediately following chemotherapy with cisplatin and 5-fluorouracil. This female patient had previously been treated with this combination with no hepatotoxicity. The elevated liver enzymes quickly normalized after chemotherapy was stopped. There were no specific changes in liver imaging. As hepatotoxicity occurred after repeated administration of cisplatin, we suggest that this hepatotoxicity might represent a case of allergic hepatitis caused by cisplatin. Severe hepatotoxicity should be watched for with repeated administration of cisplatin.


Cisplatin 5-Fluorouracil Hepatotoxicity 




Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kato H, Nakajima M (2013) Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg. 61(6):330–335CrossRefGoogle Scholar
  2. 2.
    Heath EI, Burtness BA, Heitmiller RF et al (2000) Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 18(4):868–876CrossRefGoogle Scholar
  3. 3.
    Herskovic A, Martz K, Al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326(24):1593–1598CrossRefGoogle Scholar
  4. 4.
    Yamazaki H, Ogawa M, Horikoshi N et al (1986) Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors. Gan To Kagaku Ryoho 13(8):2568–2572PubMedGoogle Scholar
  5. 5.
    Common Terminology Criteria for Adverse Events (CTCAE) (2017) Available via DIALOG. Accessed Nov 2019
  6. 6.
    Nomura M, Kato K, Ando N et al (2017) Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). Jpn J Clin Oncol 47(6):480–486CrossRefGoogle Scholar
  7. 7.
    Ando N, Kato H, Igaki H et al (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19(1):68–74CrossRefGoogle Scholar
  8. 8.
    Sugarbaker PH, Gianola FJ, Speyer JC et al (1985) Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 98(3):414–422PubMedGoogle Scholar
  9. 9.
    Fluorouracil. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. PMID: 31644088. Available via DIALOG. Accessed Nov 2019
  10. 10.
    Vestfrid MA, Castelleto L, Giménez PO (1972) Diffuse liver necrosis in treatment with 5-fluorouracil. Rev Clin Esp 125(6):549–550PubMedGoogle Scholar
  11. 11.
    Mitani S, Kadowaki S, Komori A et al (2017) Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature. Medicine (Baltimore) 96(22):e6874CrossRefGoogle Scholar
  12. 12.
    Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4(6):889–901CrossRefGoogle Scholar
  13. 13.
    Sumiyoshi M, Soda H, Sadanaga N et al (2017) Alert regarding cisplatin-induced severe adverse events in cancer patients with xeroderma pigmentosum. J Japan Soc Internal Med 56(8):979–982CrossRefGoogle Scholar
  14. 14.
    Hajj A, Ghosn M, Mourad D et al (2017) Lethal hepatotoxicity following 5-fluorouracil/cisplatin chemotherapy: a relevant case report. Per Med 4(3):197–201CrossRefGoogle Scholar
  15. 15.
    Makrilia N, Syrigou E, Kaklamanos I et al (2010) Saif MW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based DrugsGoogle Scholar
  16. 16.
    Wit FW, Kesselring AM, Gras L et al (2008) Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment naive patients: the ATHENA Cohort Study. Clin Infect Dis 46(6):933–940CrossRefGoogle Scholar
  17. 17.
    Saxon CJ, Helbert MR, Komolafe AJ et al (2014) Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? Int J STD AIDS 25(3):228–230CrossRefGoogle Scholar
  18. 18.
    Atsushi S, Akiko S, Susumu T (2003) Hypersensitivity reactions to cancer chemotherapeutic agents. Japan J Cancer Chemother 30(6):793–800Google Scholar
  19. 19.
    Shlebak AA, Clark PI, Green JA (1995) Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35(4):349–351CrossRefGoogle Scholar

Copyright information

© The Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Ayaka Yaegashi
    • 1
    Email author
  • Kensuke Yoshida
    • 1
  • Naoto Suzuki
    • 1
  • Izumi Shimada
    • 1
  • Yusuke Tani
    • 2
  • Yasuo Saijo
    • 3
  • Akira Toyama
    • 1
  1. 1.Department of PharmacyNiigata University Medical and Dental HospitalNiigataJapan
  2. 2.Department of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental SciencesNiigata UniversityNiigataJapan
  3. 3.Department of Medical Oncology, Graduate School of Medical and Dental SciencesNiigata UniversityNiigataJapan

Personalised recommendations